Skip to main content

Select Drug Profiles

New Directions in the Treatment of Multiple Myeloma: Reports on Carfilzomib-Based Therapy from ASH 2012
Lynne Lederman, PhD, R. Donald Harvey, PharmD, FCCP, BCOP, Beth Faiman, PhD(c), MSN, APRN-BC, AOCN, Atheer A. Kaddis, PharmD
Read More
Leukemia, Oncology
Initial Choice of TKI in Patients with CML Probably Not Important
Mark Knight
Read More
FDA Approvals
Ponatinib: New Option for the Treatment of Adults with CML or Ph+ ALL that Is Resistant or Intolerant to Previous Therapy with Tyrosine Kinase Inhibitors
Lynne Lederman, PhD
Read More
Perspectives
New Data Presented at Highlight Challenges and Opportunities for Payers
Matthew Mitchell, PharmD, MBA, FAMCP
Read More
Multiple Myeloma, Oncology
Oral Proteasome Inhibitor MLN9708 a News Maker at ASH 2012
Caroline Helwick
Read More
Multiple Myeloma, Oncology
Four-Drug Induction and 2-Drug Maintenance Boost Overall Survival in Patients with Newly Diagnosed Myeloma
Audrey Andrews
Read More
Multiple Myeloma, Oncology
Host Factors Important in Patients with Myeloma
Caroline Helwick
Read More
Multiple Myeloma, Oncology
New Data Demonstrate Overall Survival Benefit with Pomalidomide in Advanced Myeloma
Caroline Helwick
Read More
Leukemia, Oncology
Evidence Lacking for Eliminating Prophylactic Platelet Transfusions
Audrey Andrews
Read More
Lymphoma
Bendamustine plus Rituximab Noninferior to Standard Chemotherapy for Indolent Non-Hodgkin and Mantle-Cell Lymphomas
Caroline Helwick
Read More
Page 182 of 244
Results 1811 - 1820 of 2434